Paper Details

  1. Home
  2. Paper Details

Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studies.

Author: BorroniMaria E, HansenVincent, JordanKarin, KarthausMeinolf, RizziGiada, RossiGiorgia, RugoHope S, SchwartzbergLee

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Oral NEPA (netupitant-palonosetron) was highly effective in preventing chemotherapy-induced nausea and vomiting (CINV) over multiple chemotherapy cycles. NEPA was superior to palonosetron in preventing CINV across 4 cycles of anthracycline-cyclophosphamide (AC)-based chemotherapy.
Paper Details　
Original Abstract of the Article :
AIM: To assess the efficacy of oral NEPA (netupitant-palonosetron 300/0.50 mg) over multiple chemotherapy cycles. METHODS: Two randomized phase III studies evaluated a single dose of oral NEPA given on day 1 in chemotherapy-naive patients receiving anthracycline-cyclophosphamide (AC)-based (Study 1...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536946/

データ提供：米国国立医学図書館（NLM）

NEPA: A New Frontier in Preventing Chemotherapy-Induced Nausea and Vomiting

Navigating the harsh terrain of chemotherapy can be a daunting experience for many cancer patients, often accompanied by debilitating side effects. This research explores the effectiveness of oral NEPA (netupitant-palonosetron) as a preventative measure against acute and delayed chemotherapy-induced nausea and vomiting (CINV). The study aimed to assess NEPA's efficacy over multiple chemotherapy cycles.

The results suggest that oral NEPA holds significant promise as a preventative strategy for CINV. In two randomized, double-blind phase III studies, NEPA demonstrated superior efficacy in preventing CINV compared to other antiemetic medications. The study also revealed that NEPA's effectiveness remained consistent across multiple chemotherapy cycles, making it a reliable option for managing this common side effect.

NEPA Offers a New Hope for Managing CINV

These findings provide compelling evidence for the effectiveness of NEPA in preventing CINV. The study's results could lead to improved quality of life for cancer patients undergoing chemotherapy, reducing the burden of nausea and vomiting and allowing them to focus on their recovery journey.

A More Comfortable Chemotherapy Journey

By offering effective prevention of CINV, NEPA can potentially make the chemotherapy experience more bearable for cancer patients. This could translate into improved compliance with treatment regimens and potentially better outcomes. NEPA is a beacon of hope, guiding patients towards a more comfortable journey through their cancer treatment.

Dr. Camel's Conclusion

Much like a desert oasis provides respite from the harsh elements, NEPA offers a potential haven for cancer patients battling the discomfort of CINV. This research highlights the potential for NEPA to make chemotherapy a more manageable experience, allowing patients to focus on healing and regaining their strength.

Date :
  1. Date Completed 2020-06-10
  2. Date Revised 2023-10-11
Further Info :

Pubmed ID

30968588

DOI: Digital Object Identifier

PMC6536946

Related Literature

Article Analysis
・Effects of netupitant and palonosetron
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.